Literature DB >> 7786003

Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.

S S Park1, D J D'Amico, B Paton, A S Baker.   

Abstract

We investigated the efficacy of oral fluconazole, alone or in combination with oral flucytosine (5FC), in treating Candida endophthalmitis using a rabbit model. Albino rabbits were infected with an intravitreal inoculation of 1,000 CFU of susceptible Candida albicans and randomized 5 days later to receive treatment with oral fluconazole alone (80 mg/kg of body weight per day), a combination of fluconazole and 5FC (100 mg/kg/12 h), or no treatment. The treatment effect was assessed at 2 and 4 weeks after therapy by funduscopy, quantitative vitreous culture, and histopathology. Intravitreal levels of fluconazole, 2 to 24 h after the first dose, were measured to be > 10 times the MIC of the drug for C. albicans. Among rabbits treated with fluconazole for 2 weeks, 67% had a > 90% reduction in fungal load (P < 0.05) and 33% were sterile. After 4 weeks, all had a > 99% reduction in fungal load (P < 0.05) and 75% were sterile (P = 0.01). This treatment effect was unchanged 4 weeks after discontinuation of fluconazole. Among rabbits treated with fluconazole and 5FC for 2 weeks, 67% died during therapy. Among the surviving rabbits, 75% had a > 90% reduction in fungal load (P < 0.05) and 25% were sterile. We conclude that oral fluconazole may be useful for treatment of Candida endophthalmitis. Addition of 5FC was associated with high toxicity and minimal additional antifungal effect in our rabbit model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7786003      PMCID: PMC162661          DOI: 10.1128/AAC.39.4.958

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection.

Authors:  S C Harris; J E Wallace; G Foulds; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.

Authors:  M A Fisher; S H Shen; J Haddad; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Candida albicans endophthalmitis in a patient with AIDS. Case report.

Authors:  M H Heinemann; A F Bloom; J Horowitz
Journal:  Arch Ophthalmol       Date:  1987-09

Review 4.  Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts.

Authors:  T J Walsh; J Lee; S Aoki; F Mechinaud; J Bacher; J Lecciones; V Thomas; M Rubin; P A Pizzo
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

Review 5.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

Review 6.  Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit.

Authors:  J R Perfect
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

7.  Endogenous Candida endophthalmitis. Management without intravenous amphotericin B.

Authors:  R D Brod; H W Flynn; J G Clarkson; S C Pflugfelder; W W Culbertson; D Miller
Journal:  Ophthalmology       Date:  1990-05       Impact factor: 12.079

8.  [Fluconazole treatment of systemic mycoses].

Authors:  T Mori; M Matsumura; T Ebe; M Takahashi; T Kohara; M Inagaki; H Isonuma; I Hibiya; T Hamamoto; K Watanabe
Journal:  Jpn J Antibiot       Date:  1989-01

9.  Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents.

Authors:  P A Robinson; A K Knirsch; J A Joseph
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

10.  A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections.

Authors:  J W Van't Wout; H Mattie; R van Furth
Journal:  J Antimicrob Chemother       Date:  1988-05       Impact factor: 5.790

View more
  6 in total

1.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.

Authors:  P Phillips; S Shafran; G Garber; C Rotstein; F Smaill; I Fong; I Salit; M Miller; K Williams; J M Conly; J Singer; S Ioannou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-05       Impact factor: 3.267

Review 2.  Current approach to postoperative endophthalmitis.

Authors:  G Sunaric-Mégevand; C J Pournaras
Journal:  Br J Ophthalmol       Date:  1997-11       Impact factor: 4.638

3.  Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.

Authors:  A Louie; W Liu; D A Miller; A C Sucke; Q F Liu; G L Drusano; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans.

Authors:  Scott W Mueller; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2011-03-26

5.  Unexpected candidemia complicating ureteroscopy and urinary stenting.

Authors:  M Gross; H Winkler; S Pitlik; M Weinberger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

6.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.